Rozlytrek (entrectinib capsules and oral pellets – Genentech) — Cigna
Non-Small Cell Lung Cancer (NSCLC) with ROS1-positive metastatic disease
Initial criteria
- Patient age ≥ 18 years
- Patient has metastatic disease
- Patient has ROS1-positive disease
- Mutation was detected by an approved test
Approval duration
1 year